Oryzon Genomics Current Valuation vs. Total Debt
| ORY Stock | EUR 1.62 0.06 3.85% |
For Oryzon Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oryzon Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oryzon Genomics SA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oryzon Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oryzon Genomics SA over time as well as its relative position and ranking within its peers.
Oryzon |
Oryzon Genomics SA Total Debt vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oryzon Genomics's current stock value. Our valuation model uses many indicators to compare Oryzon Genomics value to that of its competitors to determine the firm's financial worth. Oryzon Genomics SA is rated top company in current valuation category among its peers. It also is rated top company in total debt category among its peers making up about 0.10 of Total Debt per Current Valuation. The ratio of Current Valuation to Total Debt for Oryzon Genomics SA is roughly 10.35 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Oryzon Genomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Oryzon Genomics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Oryzon Current Valuation vs. Competition
Oryzon Genomics SA is rated top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 19.45 Billion. Oryzon Genomics maintains roughly 107.12 Million in current valuation contributing less than 1% to equities under Health Care industry.
Oryzon Total Debt vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Oryzon Genomics |
| = | 107.12 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Oryzon Genomics |
| = | 10.35 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Oryzon Total Debt vs Competition
Oryzon Genomics SA is rated top company in total debt category among its peers. Total debt of Health Care industry is now estimated at about 9.16 Billion. Oryzon Genomics adds roughly 10.35 Million in total debt claiming only tiny portion of equities under Health Care industry.
Oryzon Genomics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oryzon Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oryzon Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Oryzon Genomics' change in net profit over the period of time. It can combine multiple indicators of Oryzon Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. Oryzon Genomics S.A. was founded in 2000 and is based in Barcelona, Spain. ORYZON GENOMICS operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 40 people.
Oryzon Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oryzon Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oryzon Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oryzon Genomics' important profitability drivers and their relationship over time.
Use Oryzon Genomics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oryzon Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oryzon Genomics will appreciate offsetting losses from the drop in the long position's value.Oryzon Genomics Pair Trading
Oryzon Genomics SA Pair Trading Analysis
The ability to find closely correlated positions to Oryzon Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oryzon Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oryzon Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oryzon Genomics SA to buy it.
The correlation of Oryzon Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oryzon Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oryzon Genomics SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oryzon Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Oryzon Genomics position
In addition to having Oryzon Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small & Mid Caps ETFs Thematic Idea Now
Small & Mid Caps ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small & Mid Caps ETFs theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small & Mid Caps ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Oryzon Stock
To fully project Oryzon Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Oryzon Genomics SA at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Oryzon Genomics' income statement, its balance sheet, and the statement of cash flows.